Electronic issue of blood components

AI Summary

This regulatory guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) outlines the standards for the electronic issue of blood components within the United Kingdom. Although the document serves as general guidance rather than an inspection report for a specific company or date, it applies to all blood establishments and transfusion laboratories. The regulatory framework is defined by the Blood Safety and Quality Regulations (SI 2005 No. 50, as amended), specifically Regulation 9(1)b, which incorporates Commission Directive 2005/62/EC regarding quality system standards. Key requirements include the integration of British Committee for Standards in Haematology (BCSH) guidelines for blood bank computing and compatibility procedures. The main focus is to prevent issues such as technical failures in automated release systems or non-compliance with quality specifications. Required actions for organizations include establishing a comprehensive quality management system that ensures electronic systems are validated for safety, maintaining strict adherence to compatibility protocols, and ensuring that software systems used for blood component release meet all national standards to prevent transfusion errors.